Clinical Trial Update: Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating sugammadex as a reversal agent for patients extubated immediately after isolated coronary artery bypass grafting surgery.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Bypass Grafting
• Coronary Artery Disease

Drugs mentioned

• Sugammadex (sugammadex)

Snippet

Sponsor: West Virginia University | Conditions: Surgery, Coronary Artery Disease | Phase 4 | Status: COMPLETED | Results posted: 2023-12-22